2024
Clinical Reasoning: Perspectives of Expert Clinicians on Reasoning Through Complex Clinical Cases
Donroe J, Egger E, Soares S, Sofair A. Clinical Reasoning: Perspectives of Expert Clinicians on Reasoning Through Complex Clinical Cases. Cureus 2024, 16: e51696. PMID: 38313894, PMCID: PMC10838525, DOI: 10.7759/cureus.51696.Peer-Reviewed Original ResearchComplex clinical casesClinical casesExpert cliniciansPrimary care physiciansDiagnostic errorsClinical reasoningCare physiciansSemi-structured guideCore clinical skillsMost doctorsComplex casesPatient's bedsideStudy institutionPatient contextPhysiciansClinical skillsCliniciansClinical reasoning strategiesBedsideClinical reasoning skillsThematic analysis
2002
Comparison of Visual and Spectrophotometric Methods of Broth Microdilution MIC End Point Determination and Evaluation of a Sterol Quantitation Method for In Vitro Susceptibility Testing of Fluconazole and Itraconazole against Trailing and Nontrailing Candida Isolates
Arthington-Skaggs BA, Lee-Yang W, Ciblak MA, Frade JP, Brandt ME, Hajjeh RA, Harrison LH, Sofair AN, Warnock A. Comparison of Visual and Spectrophotometric Methods of Broth Microdilution MIC End Point Determination and Evaluation of a Sterol Quantitation Method for In Vitro Susceptibility Testing of Fluconazole and Itraconazole against Trailing and Nontrailing Candida Isolates. Antimicrobial Agents And Chemotherapy 2002, 46: 2477-2481. PMID: 12121921, PMCID: PMC127334, DOI: 10.1128/aac.46.8.2477-2481.2002.Peer-Reviewed Original ResearchConceptsEnd pointSterol quantitation methodActive population-based surveillanceCandida sppPopulation-based surveillanceVisual end pointMIC end pointsC. albicans isolatesAzole antifungal agentsComparison of VisualClinical Laboratory StandardsBloodstream isolatesVitro Susceptibility TestingCandida isolatesSusceptibility testingItraconazoleAlbicans isolatesFluconazoleMIC resultsNational CommitteeVivo outcomesAntifungal agentsGrowth inhibitionC. tropicalisLaboratory StandardsSurveillance for Unexplained Deaths and Critical Illnesses
Hajjeh RA, Relman D, Cieslak PR, Sofair AN, Passaro D, Flood J, Johnson J, Hacker JK, Shieh WJ, Hendry RM, Nikkari S, Ladd-Wilson S, Hadler J, Rainbow J, Tappero JW, Woods CW, Conn L, Reagan S, Zaki S, Perkins BA, Deaths F, Group C. Surveillance for Unexplained Deaths and Critical Illnesses. Emerging Infectious Diseases 2002, 8: 145-153. PMID: 11897065, PMCID: PMC2732455, DOI: 10.3201/eid0802.010165.Peer-Reviewed Original ResearchConceptsCritical illnessMedian ageInfectious causesUnexplained deathEmerging Infections Program sitesPatients' median ageCommon clinical presentationPopulation-based surveillanceYears of ageClinical presentationEpidemiologic featuresPolymerase chain reaction-based methodSerologic testsHealthy personsDiagnostic capacityReaction-based methodsRoutine testingIllnessDeathCauseAgeSurveillanceProgram sitesSyndromeEtiologyHepatitis C. Part 2. Consultant
Sofair, AN. Hepatitis C. Part 2. Consultant. 2002 42(4): 465-473.Peer-Reviewed Original ResearchHepatitis C. Part 1.
Sofair, AN. Hepatitis C. Part 1. Consultant. 2002 42(2): 157-161.Peer-Reviewed Original Research
2001
Anthrax-what you-and your patients-need to know now.
Bia, F. and Sofair, AN. Anthrax-what you-and your patients-need to know now. Consultant. 2001 41(14): 1797-1805.Peer-Reviewed Original Research